Second Sight Medical Products (NASDAQ:EYES) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
This is a breakdown of recent recommendations and price targets for Second Sight Medical Products and ENDRA Life Sciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
|ENDRA Life Sciences||0||0||3||0||3.00|
Second Sight Medical Products presently has a consensus price target of $5.00, indicating a potential upside of 488.24%. ENDRA Life Sciences has a consensus price target of $6.00, indicating a potential upside of 466.04%. Given Second Sight Medical Products’ higher probable upside, equities analysts plainly believe Second Sight Medical Products is more favorable than ENDRA Life Sciences.
This table compares Second Sight Medical Products and ENDRA Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-553.01%||-248.94%||-153.13%|
|ENDRA Life Sciences||N/A||-347.34%||-242.82%|
Risk & Volatility
Second Sight Medical Products has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
Valuation & Earnings
This table compares Second Sight Medical Products and ENDRA Life Sciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Second Sight Medical Products||$6.90 million||15.30||-$35.09 million||($0.52)||-1.63|
|ENDRA Life Sciences||$10,000.00||702.78||-$9.80 million||($2.10)||-0.50|
ENDRA Life Sciences has lower revenue, but higher earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
5.9% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 16.3% of ENDRA Life Sciences shares are owned by institutional investors. 76.2% of Second Sight Medical Products shares are owned by company insiders. Comparatively, 11.4% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Second Sight Medical Products beats ENDRA Life Sciences on 7 of the 12 factors compared between the two stocks.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.